Michelle J. Boyle

Michelle J. Boyle

Auto-generated profile, based on publicly available information

Michelle J. Boyle

Burnet Institute, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Cell Host & Microbe
Verified
Journal Article
Closed access
DRDavid T. Riglar
David T. Riglar
DRDave Richard
Dave Richard
DWDanny W. Wilson
Danny W. Wilson
MBMichelle J. Boyle
Michelle J. Boyle
CDChaitali Dekiwadia
Chaitali Dekiwadia
JBJake Baum
Jake Baum

31 January 2016 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
JBJames G. Beeson
James G. Beeson
DDDamien R Drew
Damien R Drew
MBMichelle J Boyle
Michelle J Boyle
GFGaoqian Feng
Gaoqian Feng
FFFreya J I Fowkes
Freya J I Fowkes
JRJack S Richards
Jack S Richards
Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum accounting for the majority of malaria, and P. vivax being a second important cause, especially in Asia, the Americas and the Pacific. During infection with Plasmodium spp., the merozoite form of the parasite invades red blood cells and replicates inside them. It is during the blood-stage of infection that malaria disease occurs and, therefore, understanding merozoite invasion, host immune responses to merozoite surface antigens, and targeting merozoite surface proteins and invasion ligands by novel vaccines and therapeutics have been important areas of research. Merozoite invasion involves multiple interactions and events, and substantial processing of merozoite surface proteins occurs before, during and after invasion. The merozoite surface is highly complex, presenting a multitude of antigens to the immune system. This complexity has proved challenging to our efforts to understand merozoite invasion and malaria immunity, and to developing merozoite antigens as malaria vaccines. In recent years, there has been major progress in this field, and several merozoite surface proteins show strong potential as malaria vaccines. Our current knowledge on this topic is reviewed, highlighting recent advances and research priorities.

1 March 2015 in Immunity
Verified
Journal Article
Open access
MBMichelle J. Boyle
Michelle J. Boyle
LRLinda Reiling
Linda Reiling
GFGaoqian Feng
Gaoqian Feng
CLChristine Langer
Christine Langer
FOFaith H. Osier
Faith H. Osier
JBJames G. Beeson
James G. Beeson
Antibodies play major roles in immunity to malaria; however, a limited understanding of mechanisms mediating protection is a major barrier to vaccine development. We have demonstrated that acquired human anti-malarial antibodies promote complement deposition on the merozoite to mediate inhibition of erythrocyte invasion through C1q fixation and activation of the classical complement pathway. Antibody-mediated complement-dependent (Ab-C') inhibition was the predominant invasion-inhibitory activity of human antibodies; most antibodies were non-inhibitory without complement. Inhibitory activity was mediated predominately via C1q fixation, and merozoite surface proteins 1 and 2 were identified as major targets. Complement fixation by antibodies was very strongly associated with protection from both clinical malaria and high-density parasitemia in a prospective longitudinal study of children. Ab-C' inhibitory activity could be induced by human immunization with a candidate merozoite surface-protein vaccine. Our findings demonstrate that human anti-malarial antibodies have evolved to function by fixing complement for potent invasion-inhibitory activity and protective immunity.

26 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMichelle J. Boyle
Michelle J. Boyle
DWDanny W. Wilson
Danny W. Wilson
JRJack Richards
Jack Richards
DRDavid T. Riglar
David T. Riglar
KTKevin K. A. Tetteh
Kevin K. A. Tetteh
JBJames G. Beeson
James G. Beeson
During blood-stage infection by Plasmodium falciparum, merozoites invade RBCs. Currently there is limited knowledge of cellular and molecular invasion events, and no established assays are available to readily measure and quantify invasion-inhibitory antibodies or compounds for vaccine and drug studies. We report the isolation of viable merozoites that retain their invasive capacity, at high purity and yield, purified by filtration of highly synchronous populations of schizonts. We show that the half-life of merozoite invasive capacity after rupture is 5 min at 37 °C, and 15 min at room temperature. Studying the kinetics of invasion revealed that 80% of invasion events occur within 10 min of mixing merozoites and RBCs. Invasion efficiency was maximum at low merozoite-to-RBC ratios and occurred efficiently in the absence of serum and with high concentrations of dialyzed nonimmune serum. We developed and optimized an invasion assay by using purified merozoites that enabled invasion-inhibitory activity of antibodies and compounds to be measured separately from other mechanisms of growth inhibition; the assay was more sensitive for detecting inhibitory activity than established growth-inhibition assays. Furthermore, with the use of purified merozoites it was possible to capture and fix merozoites at different stages of invasion for visualization by immunofluorescence microscopy and EM. We thereby demonstrate that processing of the major merozoite antigen merozoite surface protein-1 occurs at the time of RBC invasion. These findings have important implications for defining invasion events and molecular interactions, understanding immune interactions, and identifying and evaluating inhibitors to advance vaccine and drug development.

1 July 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
FOFaith Ha Osier
Faith Ha Osier
GFGaoqian Feng
Gaoqian Feng
MBMichelle J Boyle
Michelle J Boyle
CLChristine Langer
Christine Langer
JZJingling Zhou
Jingling Zhou
JBJames G. Beeson
James G. Beeson
An understanding of the mechanisms mediating protective immunity against malaria in humans is currently lacking, but critically important to advance the development of highly efficacious vaccines. Antibodies play a key role in acquired immunity, but the functional basis for their protective effect remains unclear. Furthermore, there is a strong need for immune correlates of protection against malaria to guide vaccine development.

1 February 2009 in International Journal for Parasitology
Verified
Journal Article
Closed access
JBJake Baum
Jake Baum
LCLin Chen
Lin Chen
JHJulie Healer
Julie Healer
SLSash Lopaticki
Sash Lopaticki
MBMichelle Boyle
Michelle Boyle
ACAlan F. Cowman
Alan F. Cowman